Melatonin attenuates antipsychotic metabolic effects: an eight‐week randomized, double‐blind, parallel‐group, placebo‐controlled clinical trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objective: Second‐generation antipsychotics (SGA s) are among the first‐line treatments for bipolar disorder and schizophrenia, but have a tendency to generate metabolic disturbances. These features resemble a metabolic syndrome for which a central autonomic imbalance has been proposed that may originate from the hypothalamic suprachiasmatic nuclei. In a clinical trial, we hypothesized that melatonin, a hormone that regulates the suprachiasmatic nucleus, could attenuate SGA‐induced adverse metabolic effects. Methods: In an eight‐week, double‐blind, randomized, placebo‐controlled, parallel‐group clinical trial, we evaluated the metabolic effect of melatonin in SGA‐treated patients in terms of weight, blood pressure, lipid, glucose, body composition, and anthropometric measures. A total of 44 patients treated with SGA s, 20 with bipolar disorder and 24 with schizophrenia, randomly received placebo (n = 24) or melatonin 5 mg (n = 20). Results: The melatonin group showed a decrease in diastolic blood pressure (5.1 versus 1.1 mmHg for placebo, p = 0.003) and attenuated weight gain (1.5 versus 2.2 kg for placebo, F = 4.512, p = 0.040) compared to the placebo group. The strong beneficial metabolic effects of melatonin in comparison to placebo on fat mass (0.2 versus 2.7 kg, respectively, p = 0.032) and diastolic blood pressure (5.7 versus 5.5 mmHg, respectively, p = 0.001) were observed in the bipolar disorder and not in the schizophrenia group. No adverse events were reported. Conclusions: Our results show that melatonin is effective in attenuating SGA s' adverse metabolic effects, particularly in bipolar disorder. The clinical findings allow us to propose that SGAs may disturb a centrally mediated metabolic balance that causes adverse metabolic effects and that nightly administration of melatonin helps to restore. Melatonin could become a safe and cost‐effective therapeutic option to attenuate or prevent SGA metabolic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Reppert, S. M., Weaver, D. R., & Ebisawa, T. (1994) · Neuron · doi:10.1016/0896-6273(94)90055-8 · Cited by 1,096
Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease
Wulff, K., Gatti, S., Wettstein, J. G., & Foster, R. G. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2868 · Cited by 1,055
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 1×
“Melatonin is a hormone secreted by the pineal gland that follows a circadian rhythm with increased secretion in the middle of the night (15).”
BackgroundExcess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension
Scheer, F. A. J. L., Van Montfrans, G. A., van Someren, E. J. W., Mairuhu, G., & Buijs, R. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000113293.15186.3b · Cited by 451
Sleep and circadian rhythm disruption in schizophrenia
Wulff, K., Dijk, D.-J., Middleton, B., Foster, R. G., & Joyce, E. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096321 · Cited by 426
Sleep and circadian rhythms: key components in the regulation of energy metabolism
Laposky, A. D., Bass, J., Kohsaka, A., & Turek, F. W. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.06.079 · Cited by 351 · cited 1×
“Thus, melatonin has been shown to be involved in a series of biological functions such as sleep regulation (17, 18), blood pressure (BP) (19, 20), regulation of circadian rhythms, mood, and behavior (21), and more recently the regulation of metabolic processes including insulin, leptin, and lipid regulation (20, 22, 2…”
BackgroundKoziróg, M., Poliwczak, A. R., Duchnowicz, P., Koter-Michalak, M., Sikora, J., & Broncel, M. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00835.x · Cited by 299 · cited 4×
“The BP-lowering effect of melatonin found in this study is consistent with previous clinical studies (19, 20, 43, 46) and is a desired, possibly prophylactic effect in subjects treated with SGAs (47–49).”
BackgroundResultInfluentialSrinivasan, V., Smits, M., Spence, W., Lowe, A. D., Kayumov, L., Pandi-Perumal, S. R., Parry, B., & Cardinali, D. P. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970600571822 · Cited by 292
Cited by
Melatonin as a Hormone: New Physiological and Clinical Insights
Cipolla-Neto, J., & Amaral, F. G. D. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00084 · Cited by 635
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292
Melatonin in type 2 diabetes mellitus and obesity
Karamitri, A., & Jockers, R. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0130-1 · Cited by 268
Gottlieb, J. F., Benedetti, F., Geoffroy, P. A., Henriksen, T. E. G., Lam, R. W., Murray, G., Phelps, J., Sit, D., Swartz, H. A., Crowe, M., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12847 · Cited by 196
Tye, C., Runicles, A. K., Whitehouse, A. J. O., & Alvares, G. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00751 · Cited by 177
Mitochondria: the birth place, battle ground and the site of melatonin metabolism in cells
Tan, D.-X., & Reiter, R. J. (2019) · Melatonin Research · doi:10.32794/mr11250011 · Cited by 172
Jeppesen, R., Christensen, R. H. B., Pedersen, E. M. J., Nordentoft, M., Hjorthøj, C., Köhler-Forsberg, O., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.028 · Cited by 132
Biological rhythms and chronotherapeutics in depression
Geoffroy, P. A., & Palagini, L. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110158 · Cited by 127
Disrupted sleep and circadian rhythms in schizophrenia and their interaction with dopamine signaling
Ashton, A., & Jagannath, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00636 · Cited by 106
Mohammadi-Sartang, M., Ghorbani, M., & Mazloom, Z. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.11.003 · Cited by 94
Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., White, R. F., Honer, W. G., & Barr, A. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00203 · Cited by 79
Evening chronotype as a discrete clinical subphenotype in bipolar disorder
Romo-Nava, F., Blom, T. J., Cuellar-Barboza, A. B., Winham, S. J., Colby, C. L., Nunez, N. A., Biernacka, J. M., Frye, M. A., & McElroy, S. L. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.151 · Cited by 63
Self-citationDoosti-Irani, A., Ostadmohammadi, V., Mirhosseini, N., Mansournia, M., Reiter, R., Kashanian, M., Rahimi, M., Razavi, M., & Asemi, Z. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0752-8462 · Cited by 52
Mohammadi, S., Rastmanesh, R., Jahangir, F., Amiri, Z., Djafarian, K., Mohsenpour, M. A., Hassanipour, S., & Ghaffarian-Bahraman, A. (2021) · BioMed Research International · doi:10.1155/2021/3502325 · Cited by 22
Seeman, M. V. (2016) · Journal of Obesity Management · doi:10.14302/issn.2574-450x.jom-16-1039 · Cited by 10
Metadata
- Authors
- Romo‐Nava, F., Alvarez‐Icaza González, D., Fresán‐Orellana, A., Saracco Alvarez, R., Becerra‐Palars, C., Moreno, J., Ontiveros Uribe, M. P., Berlanga, C., Heinze, G., & Buijs, R. M.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2014-03-17
- Volume
- 16
- Issue
- 4
- Pages
- 410-421
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2059032902
- Cited by
- 119
- References
- 14
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.